Literature DB >> 26703966

Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients.

Mathilde Lamarque1, Céline Bossard2, Adrien Contejean3, Pauline Brice4, Marie Parrens5, Steven Le Gouill6, Josette Brière7, Reda Bouabdallah8, Danielle Canioni9, Hervé Tilly10, Brigitte Bouchindhomme11, Emmanuel Bachy12, Richard Delarue13, Corinne Haioun14, Philippe Gaulard15.   

Abstract

Entities:  

Keywords:  brentuximab vedotin; primary cutaneous T-cell lymphoma; refractory; relapsed; systemic anaplastic large-cell lymphoma

Mesh：

Substances：

Year:  2015        PMID： 26703966      PMCID： PMC4815738          DOI： 10.3324/haematol.2015.135400

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

Review 1.  CD30 expression in peripheral T-cell lymphomas.

Authors:  Elena Sabattini; Marco Pizzi; Valentina Tabanelli; Pamela Baldin; Carlo Sagramoso Sacchetti; Claudio Agostinelli; Pier Luigi Zinzani; Stefano A Pileri
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

2.  Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels.

Authors:  Céline Bossard; Maria Pamela Dobay; Marie Parrens; Laurence Lamant; Edoardo Missiaglia; Corinne Haioun; Antoine Martin; Bettina Fabiani; Richard Delarue; Olivier Tournilhac; Mauro Delorenzi; Philippe Gaulard; Laurence de Leval
Journal:  Blood       Date:  2014-09-15       Impact factor: 22.113

3.  Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

Authors:  Barbara Pro; Ranjana Advani; Pauline Brice; Nancy L Bartlett; Joseph D Rosenblatt; Tim Illidge; Jeffrey Matous; Radhakrishnan Ramchandren; Michelle Fanale; Joseph M Connors; Yin Yang; Eric L Sievers; Dana A Kennedy; Andrei Shustov
Journal:  J Clin Oncol       Date:  2012-05-21       Impact factor: 44.544

4.  Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.

Authors:  Youn H Kim; Mahkam Tavallaee; Uma Sundram; Katrin A Salva; Gary S Wood; Shufeng Li; Sima Rozati; Seema Nagpal; Michael Krathen; Sunil Reddy; Richard T Hoppe; Annie Nguyen-Lin; Wen-Kai Weng; Randall Armstrong; Melissa Pulitzer; Ranjana H Advani; Steven M Horwitz
Journal:  J Clin Oncol       Date:  2015-07-20       Impact factor: 44.544

5.  Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.

Authors:  Eric D Jacobsen; Jeff P Sharman; Yasuhiro Oki; Ranjana H Advani; Jane N Winter; Celeste M Bello; Gary Spitzer; Maria Corinna Palanca-Wessels; Dana A Kennedy; Pamela Levine; Jing Yang; Nancy L Bartlett
Journal:  Blood       Date:  2015-01-08       Impact factor: 22.113

6.  ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.

Authors:  Kerry J Savage; Nancy Lee Harris; Julie M Vose; Fred Ullrich; Elaine S Jaffe; Joseph M Connors; Lisa Rimsza; Stefano A Pileri; Mukesh Chhanabhai; Randy D Gascoyne; James O Armitage; Dennis D Weisenburger
Journal:  Blood       Date:  2008-04-02       Impact factor: 22.113

7.  Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.

Authors:  Vivien Mak; Jeremey Hamm; Mukesh Chhanabhai; Tamara Shenkier; Richard Klasa; Laurie H Sehn; Diego Villa; Randy D Gascoyne; Joseph M Connors; Kerry J Savage
Journal:  J Clin Oncol       Date:  2013-04-22       Impact factor: 44.544

8.  International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.

Authors:  Julie Vose; James Armitage; Dennis Weisenburger
Journal:  J Clin Oncol       Date:  2008-07-14       Impact factor: 44.544

9.  Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.

Authors:  Tim Illidge; Reda Bouabdallah; Robert Chen; Ajay K Gopal; Craig H Moskowitz; Radhakrishnan Ramchandren; Andrei R Shustov; Herve Tilly; Tanya M Trippett; Adam Gibb; Laurie E Grove; Ranjana Advani
Journal:  Leuk Lymphoma       Date:  2015-01-21

10.  Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.

Authors:  Steven M Horwitz; Ranjana H Advani; Nancy L Bartlett; Eric D Jacobsen; Jeff P Sharman; Owen A O'Connor; Tanya Siddiqi; Dana A Kennedy; Yasuhiro Oki
Journal:  Blood       Date:  2014-03-20       Impact factor: 22.113
View more
  6 in total

1.  Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results.

Authors:  Daniel J Lewis; Rakhshandra Talpur; Auris O Huen; Michael T Tetzlaff; Madeleine Duvic
Journal:  JAMA Dermatol       Date:  2017-12-01       Impact factor: 10.282

2.  Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma.

Authors:  Alessandro Broccoli; Cinzia Pellegrini; Alice Di Rocco; Benedetta Puccini; Caterina Patti; Guido Gini; Donato Mannina; Monica Tani; Chiara Rusconi; Alessandra Romano; Anna Vanazzi; Barbara Botto; Carmelo Carlo-Stella; Stefan Hohaus; Pellegrino Musto; Patrizio Mazza; Stefano Molica; Paolo Corradini; Angelo Fama; Francesco Gaudio; Michele Merli; Angela Gravetti; Giuseppe Gritti; Annalisa Arcari; Patrizia Tosi; Anna Marina Liberati; Antonello Pinto; Vincenzo Pavone; Filippo Gherlinzoni; Virginia Naso; Stefano Volpetti; Livio Trentin; Maria Cecilia Goldaniga; Maurizio Bonfichi; Amalia De Renzo; Corrado Schiavotto; Michele Spina; Sergio Storti; Angelo Michele Carella; Vittorio Stefoni; Lisa Argnani; Pier Luigi Zinzani
Journal:  Haematologica       Date:  2017-08-03       Impact factor: 9.941

3.  Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

Authors:  Anne-Claire Mamez; Axelle Dupont; Didier Blaise; Patrice Chevallier; Edouard Forcade; Patrice Ceballos; Mohamad Mohty; Felipe Suarez; Yves Beguin; Regis Peffault De Latour; Marie-Thérèse Rubio; Olivier Tournilhac; Stéphanie Nguyen
Journal:  J Hematol Oncol       Date:  2020-05-19       Impact factor: 17.388

4.  FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma.

Authors:  Nicholas C Richardson; Yvette L Kasamon; Haiyan Chen; R Angelo de Claro; Jingjing Ye; Gideon M Blumenthal; Ann T Farrell; Richard Pazdur
Journal:  Oncologist       Date:  2019-03-26

Review 5.  Brentuximab vedotin: clinical updates and practical guidance.

Authors:  Jun Ho Yi; Seok Jin Kim; Won Seog Kim
Journal:  Blood Res       Date:  2017-12-26

Review 6.  Biology and Molecular Pathogenesis of Mature T-Cell Lymphomas.

Authors:  José R Cortés; Teresa Palomero
Journal:  Cold Spring Harb Perspect Med       Date:  2021-05-03       Impact factor: 6.915
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.